Federal contract award
75N93024C00070
THE PRIMARY GOAL IS THE DELINEATION OF FUNCTIONAL B CELL EPITOPES RECOGNIZED BY POTENTLY NEUTRALIZING OR PROTECTIVE ANTIBODIES TO FACILITATE FUTURE DEVELOPMENT OF SAFE AND EFFECTIVE VACCINES AND THERAPEUTICS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $5.5M |
| Current contract value | $5.5M |
| Potential contract value / ceiling | $9.1M |
| Start date | Sep 16, 2024 |
| Current end date | Sep 15, 2027 |
| Potential end date | Sep 15, 2029 |
| Latest award activity | Jul 15, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 15, 2026 | P00004 | $1.8M | EO 14398- THE PRIMARY GOAL IS THE DELINEATION OF FUNCTIONAL B CELL EPITOPES RECOGNIZED BY POTENTLY NEUTRALIZING OR PROTECTIVE ANTIBODIES TO FACILITATE FUTURE DEVELOPMENT OF SAFE AND EFFECTIVE VACCINES AND THERAPEUTICS. |
| Jun 2, 2026 | P00003 | $0 | THE PRIMARY GOAL IS THE DELINEATION OF FUNCTIONAL B CELL EPITOPES RECOGNIZED BY POTENTLY NEUTRALIZING OR PROTECTIVE ANTIBODIES TO FACILITATE FUTURE DEVELOPMENT OF SAFE AND EFFECTIVE VACCINES AND THERAPEUTICS. |
| Sep 22, 2025 | P00002 | $1.5M | THE PRIMARY GOAL IS THE DELINEATION OF FUNCTIONAL B CELL EPITOPES RECOGNIZED BY POTENTLY NEUTRALIZING OR PROTECTIVE ANTIBODIES TO FACILITATE FUTURE DEVELOPMENT OF SAFE AND EFFECTIVE VACCINES AND THERAPEUTICS. |
| Sep 11, 2025 | P00001 | $400.0K | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING: EOI BILATERAL MODIFICATION TO DESCOPE FOR FY2025 COST SAVINGS: FUNCTIONAL B-CELL EPITOPE DISCOVERY FOR ARTHROPOD-BORNE DISEASES |
| Sep 12, 2024 | 0 | $1.8M | THE PRIMARY GOAL IS THE DELINEATION OF FUNCTIONAL B CELL EPITOPES RECOGNIZED BY POTENTLY NEUTRALIZING OR PROTECTIVE ANTIBODIES TO FACILITATE FUTURE DEVELOPMENT OF SAFE AND EFFECTIVE VACCINES AND THERAPEUTICS. |
Estimated positioning window
Sep 15, 2028 – Mar 15, 2029
60/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 60/100. Available recorded signals: 55 points.
- Contract end 2029-09-15 (1056 days from calculation)
- +15 points
- 155 historical awards in this buyer and category group
- +15 points
- 5 recorded award transactions
- +10 points
- Latest award action: 2026-07-15
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Deborah Blyveis | Contact | blyveisd@niaid.nih.gov 2406695143 | Source | Jul 7, 2023 |
| Emily Bannister | Contact | emily.bannister@nih.gov 2406695135 | Source | Jul 7, 2023 |
| Deborah Blyveis | Contact | blyveisd@niaid.nih.gov 2406695143 | Source | Jun 6, 2023 |
| Emily Bannister | Contact | emily.bannister@nih.gov 2406695135 | Source | Jun 6, 2023 |
| Deborah Blyveis | Contact | blyveisd@niaid.nih.gov 2406695143 | Source | May 23, 2023 |
| Emily Bannister | Contact | emily.bannister@nih.gov 2406695135 | Source | May 23, 2023 |
| Deborah Blyveis | Contact | blyveisd@niaid.nih.gov 2406695143 | Source | May 5, 2023 |
| Emily Bannister | Contact | emily.bannister@nih.gov 2406695135 | Source | May 5, 2023 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.